[Systemic thrombolytic therapy of myocardial infarction].
Systemic thrombolytic therapy was given to 67 patients with large-focal myocardial infarction: immobilized streptokinase (streptodecase) was administered to 37 patients, and native thrombolytic drugs (streptokinase or urokinase), to 30 patients. Systemic thrombolytic therapy initiated within 6 hours of the attack was shown to affect favorably the course of myocardial infarction, as manifested in a significant reduction of the incidence of protracted disease and arrhythmias, and rapid elimination of congestive heart failure. The two regimens being equally effective in clinical terms, immobilized streptokinase was associated with considerably reduced rates of specific side-effects common to thrombolytic therapy.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy* / Q000503:physiopathology; D004800:Enzymes, Immobilized / Q000627:therapeutic use; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D005500:Follow-Up Studies; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D013300:Streptokinase / Q000627:therapeutic use*; D013997:Time Factors; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
D004800:Enzymes, Immobilized; D013300:Streptokinase; D014568:Urokinase-Type Plasminogen Activator
Sistemnaia tromboliticheskaia terapiia pri infarkte miokarda.